checkAd
    Startseite > Aktien > Tiziana Life Sciences > Nachrichten
    Tiziana Life Sciences Aktie
    1,4200
     
    EUR
    +10,94 %
    +0,1400 EUR
    Letzter Kurs 21.10.21 Tradegate
    1,3900
     
    EUR
    1.190 STK
    Geldkurs 20.10.21
    1,4500
     
    EUR
    1.140 STK
    Briefkurs 20.10.21
    ISIN: US88875G1013 · WKN: A2PTNF · Großbritannien

    Neueste Nachrichten

    Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research
    30.05.24 · globenewswire · Tiziana Life Sciences
    Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab
    13.05.24 · globenewswire · Tiziana Life Sciences
    Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
    25.04.24 · globenewswire · Tiziana Life Sciences
    Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
    23.04.24 · globenewswire · Tiziana Life Sciences
    Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
    22.04.24 · globenewswire · Tiziana Life Sciences
    Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today
    19.04.24 · globenewswire · Tiziana Life Sciences
    Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
    18.04.24 · globenewswire · Tiziana Life Sciences
    Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
    11.04.24 · globenewswire · Tiziana Life Sciences
    Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease
    05.03.24 · globenewswire · Tiziana Life Sciences
    Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
    08.01.24 · globenewswire · Tiziana Life Sciences
    Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
    05.01.24 · globenewswire · Tiziana Life Sciences
    Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation
    05.01.24 · globenewswire · Tiziana Life Sciences